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Rapport de synthèse 
Contexte 
Les programmes de prévention cardiovasculaire secondaire après un événement coronarien 
aigu ont pu démontrer leur efficacité dans le contexte des soins ambulatoires. L'hospitalisation 
pour une maladie aiguë peut être considérée comme un « instant charnière», particulièrement 
adapté à un changement de comportement de santé et où des interventions de prévention 
secondaire, telle l'éducation du patient, pourraient être particulièrement efficaces. De plus, la 
prescription de médicaments de prévention cardiovasculaire durant l'hospitalisation semble 
augmenter la proportion des patients traités selon les recommandations sur le long terme. 
Récemment, plusieurs études ont évalué l'efficacité de programmes de prévention ayant pour 
but l'éducation des patients et/ou une augmentation du taux de prescription de médicaments 
prouvés efficaces par les médecins en charge. L'article faisant l'objet du travail de thèse 
synthétise la littérature existante concernant l'efficacité en termes de mortalité des 
interventions multidimensionnelles de prévention cardiovasculaire après un syndrome 
coronarien aigu, débutées à l'hôpital, centrées sur le patient et ciblant plusieurs facteurs de 
risque cardiovasculaire. 
Méthode et Résultats 
En utilisant une stratégie de recherche définie à l'avance, nous avons inclus des essais 
cliniques avec groupe contrôle et des études avant-après, débutées à l'hôpital et qui incluaient 
des résultats cliniques de suivi en terme de mortalité, de taux de réadmission et/ou de récidive 
de syndrome coronarien aigu. Nous avons catégorisé les études selon qu'elles ciblaient les 
patients (par exemple une intervention d'éducation aux patients par des infirmières), les 
soignants (par exemple des cours destinés aux médecins-assistants pour leur enseigner 
comment prodiguer des interventions éducatives) ou le système de soins (par exemple la mise 
en place d'itinéraires cliniques au niveau de l'institution). 
Globalement, les interventions rapportées dans les 14 études répondant aux critères 
montraient une réduction du risque relatif (RR) de mortalité après un an (RR= 0.79; 95% 
intervalle de confiance (IC), 0.69-0.92; n=37'585). Cependant, le bénéfice semblait dépendre 
du type d'étude et du niveau d'intervention. Les études avant-après suggéraient une réduction 
du risque de mortalité (RR, 0.77; 95% IC, 0.66-0.90; n=3680 décès), tandis que le RR était de 
0.96 (95% IC, 0.64-1.44; n=99 décès) pour les études cliniques contrôlées. Seules les études 
avant-après et les études ciblant les soignants et le système, en plus de cibler les patients, 
semblaient montrer un bénéfice en termes de mortalité à une année. 
Conclusions et perspectives 
Les preuves d'efficacité des interventions de prévention secondaires débutées à l'hôpital, 
ciblant le patient, sont prometteuses, mais pas définitives. En effet, seules les études avant-
après montrent un bénéfice en termes de mortalité. Les recherches futures dans ce domaine 
devraient tester formellement quels éléments des interventions amènent le plus de bénéfices 
pour les patients. 
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Efficacy of In-Hospital Multidimensional Interventions of 
Secondary Prevention After Acute Coronary Syndrome 
A Systematic Review and Meta-Analysis 
Reto Auer, MD; Jacques Gaume, MA; Nicolas Rodondi, MD, MAS; 
Jacques Cornuz, MD, MPH; William A. Ghali, MD, MPH 
Background-Secondary prevention programs for patients experiencing an acute coronary syndrome have been shown to 
be effective in the outpatient setting. The efficacy of in-hospital prevention interventions administered soon after acute 
cardiac events is unclear. We performed a systematic review and meta-analysis to determine whether in-hospital, 
patient-level interventions targeting multiple cardiovascular risk factors reduce all-cause mortality after an acute 
coronary syndrome. 
Methods and Results-Using a prespecified search strategy, we included controlled clinical trials and before-after studies 
of secondary prevention interventions with at least a patient-level component (ie, education, counseling, or 
patient-specific order sets) initiated in hospital with outcomes of mortality, readmission, or reinfarction rates in acute 
coronary syndrome patients. We classified the interventions as patient-level interventions with or without associated 
healthcare provider-level interventions and/or system-level interventions. Twenty-six studies met our inclusion criteria. 
The summary estimate of 14 studies revealed a relative risk of all-cause mortality of 0.79 (95% CI, 0.69 to 0.92; 
n=37'585) at 1 year. However, the apparent benefit depended on study design and level of intervention. The before-after 
studies suggested reduced mortality (relative risk [RR], 0.77; 95% CI, 0.66 to 0.90; n=3680 deaths), whereas the RR 
was 0.96 (95% CI, 0.64 to 1.44; n =99 deaths) among the controlled clinical trials. Only interventions including a 
provider- or system-level intervention suggested reduced mortality compared with patient-level-only interventions. 
Conclusions-The evidence for in-hospital, patient-level interventions for secondary prevention is prornising but not 
definitive because only before-after studies suggest a significant reduction in mortality. Future research should formally 
test which components of interventions provide the greatest benefit. (Circulation. 2008;117:3109-3117.) 
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Guidelines developed by the American Heart Association/ American College of Cardiology recommend pharma-
cological and lifestyle interventions to reduce recurrent 
events in patients with ST-segment myocardial infarction and 
non-ST-segment elevation myocardial infarction. 1 •2 A variety 
of outpatient secondary prevention programs have demon-
strated their efficacy in prior systematic reviews of random-
ized controlled trials.3•4 Beginning secondary prevention 
while the patient is in hospital might further improve 
outcomes. 
Clinical Perspective p 3117 
Inpatient education after myocardial infarction might have 
an impact on cardiovascular risk factor (CVRF) management, 
as suggested by a review of inpatient education interven-
tions. 5 In-hospital smoking cessation counseling interventions 
Received October 23, 2007; accepted March 27, 2008. 
during the hospital stay appear effective in a systematic 
review of randomized controlled trials, although they have 
not been specifically reviewed systematically for patients 
with recent myocardial infarction,6 Interest in the inpatient 
setting for secondary prevention is heightened by the recog-
nized potential of hospitalization after an acute illness as a 
"teachable moment" for behavioral change that may increase 
the benefit of counselîng interventions delivered to hospital-
ized patients.7 
Barly, in-hospital initiation of preventive therapies might 
increase the likelihood of being adequately treated. 8 In recent 
years, multiple studies have assessed pragmatic interventions 
targeting an increase in prescription rates by physicians 
and/or long-term medication adherence by patients.9•10 How-
ever, these interventions have not yet been systematically 
reviewed or meta-analyzed. Furthermore, the interventions 
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have not been formally stratified according to levels of 
intervention, as proposed for the categorization of interven-
tions targeting long-term adherence. 11 Recognizing this, we 
conducted a systematic review to determine whether in-
hospital secondary prevention interventions improve out-
comes of patients who have suffered an acute coronary 
syndrome. 
Methods 
Categorizing the Intervention 
In conducting our review, we categorized secondary prevention 
programs described in the literature on the basis of a conceptual 
mode! that considers the levels of intervention. 11 The first tier, 
patient-level interventions, targets patients directly through counsel-
ing, education, or patient-specific order sets. To be included in our 
systematic review, interventions had to involve at least the patient 
level. Second, healthcare provider-level interventions included those 
that tried to change the attitudes or knowledge of healthcare 
providers (eg, improving physician's skills and effectiveness in 
counseling through an educational program or education/reminders 
on benefits of specific therapies). 12 Third, system-level interventions 
involved a global change in the organization of care (eg, critical 
pathways or facility outcome reporting). 13 Our systematic review 
thus includes at least patient-level interventions, with some operating 
additionally at the provider and/or system levels. 
Study Selection 
To be selected in our review, studies had to fulfill 6 inclusion criteria. 
First, the studied population had to be patients hospitalized for an 
acute coronary syndrome, defined as unstable angina, non-ST-
segment myocardial infarction, or ST-segment myocardial infarc-
tion. Second, the intervention had to be a patient-level intervention 
(ie, at least a part of the intervention had to targe! the patient directly 
through education, counseling, or patient-specific order sets). Third, 
the intervention had to target multiple CVRFs (at least 2 among 
smoking cessation, blood pressure, blood lipids, diet, weight, and 
physical activity) or an increase in > 1 efficacious secondary 
prevention drug therapy (antiplatelet agents, {3-blockers, angioten-
sin-converting enzyme inhibitors, blood lipid-lowering drug). 
Fourth, intervention had to be initiated during the hospital stay. Fifth, 
the study had to report follow-up clinical outcomes after the hospital 
stay like mortality, readmission rates, reinfarction rates, or CVRF 
contrai (smoking cessation, blood lipids control, diet change, weight 
reduction, and physical activity improvement). And sixth, studies 
had to describe a comparison between patients receiving an inter-
vention and patients not receiving the intervention (ie, a contrai 
group). 
The exclusion criteria were studies assessing only the impact of 
invasive procedures (ie, angiography, coronary artery bypass graft 
surgery) or early revascularization interventions (eg, thrombolysis). 
We also excluded interventions aimed only at changing professional 
behavior or the healthcare system and thus not directly involving the 
patient. 
Out~omes 
The primary outcome of interest was ail-cause mortality at follow-
up. Secondary outcomes were differences in readmission rates or 
reinfarction rates, CVRF contrai at follow-up, and the percent of 
patients leaving the hospital with proven beneficial medications. 
Search Strategy 
We structured our search to identify clinical trials and before-after 
studies of secondary prevention interventions initiated in hospital 
that provided follow-up outcomes of mortality, readmission rates, or 
CVRF contrai in patients with acute coronary syndrome using bath 
electronic and manual search strategies. Ali languages were consid-
ered eligible. 
We searched MEDLINE (1966 through March 2007), EMBASE 
(1980 through March 2007), CINAHL (1982 through March 2007), 
PsycINFO (1967 through March 2007) database, and the Cochrane 
Controlled Clinical Trial register (1996 through March 2007) using 
a recommended approach for systematic reviews of randomized 
trials. 14 For MEDLINE, we derived 4 comprehensive search themes 
that were combined with the Boolean operator "and." We created the 
first theme representing our patient population of interest by using an 
exploded MeSH heading for the term "Myocardial Ischemia/nu, pc, 
dh, dt, th" (nursing, prevention and contrai, diet therapy, drug 
therapy, therapy). We created the second theme for the interventions 
of interest by using the Boolean search term "or" to search for the 
following terms appearing as exploded MeSH headings: "health 
services administration" or "health promotion" or "caregivers/ed" 
(education) or "rehabilitation" or "health behavior" or "risk reduc-
tion behavior" or "tobacco use cessation" or the terms appearing as 
text words: "brief.mp" (mp is title, original title, abstract, name of 
substance word, subject heading word) or "multip$.mp." The third 
theme for the intervention setting of interest was created by using the 
exploded MeSH headings "hospitals" or "inpatients" or the unex-
ploded MeSH headings "hospitalization" or "patient discharge" or 
the term appearing as the text word "hospital setting$.mp." The 
fourth theme for study design used a highly sensitive study filter for 
interventional studies (bath controlled clinicat trials and before-after 
studies). 14•15 For EMBASE, CINAHL, and PsycINFO, we adapted 
the MeSH terms to the MeSH terms of the searched database. For the 
Cochrane Controlled Clinicat Trial register, we used a similar search 
strategy by text words only in which the comprehensive search 
themes "patient population" and "intervention" were combined using 
the Boolean term "and." 
Data Extraction and Quality Assessment 
In a 2-step selection process, 2 investigators (R.A. and J.G.) 
independently reviewed the tilles and abstracts of ail citations to 
identify studies meeting inclusion criteria. In addition, 1 investigator 
(R.A.) screened the reference list of identified studies for other 
potentially relevant studies. The same 2 investigators reviewed the 
relevant reports in full text for eligibility and independently extracted 
data from ail studies fulfilling eligibility criteria. Data extracted 
included characteristics of the intervention, type of study, baseline 
clinical characteristics of the participants, and relevant outcomes. 
Authors of the studies were contacted for additional information 
when applicable. Because data on cause-specific mortality (eg, 
cardiovascular mortality) were rarely reported as such, we abstracted 
the data for ail-cause mortality only. We decided not to abstract the 
secondary outcomes on CVRF control of blood pressure contrai, 
physical activity, diet change, and weight contrai initially targeted 
for our systematic review because they were rarely and/or variably 
reported among' the selected studies. 
We categorized the studies according to their design into clinical 
trials (involving allocation of individual patients to intervention and 
contrai groups) and before-after studies. We considered study design 
as the primary study quality measure. For the clinical trials, we also 
reported on study quality with the Jadad et al1 6 quality score, 
adapting it to the present situation. We did not include blinding of 
study participants to intervention because it is difficult to achieve in 
the study of lifestyle interventions. Items to assess study quality were 
methods of randomization (2 points) and reporting of losses to 
follow-up (1 point), thus leading to a maximum score of 3 points for 
study quality.17 
Statistical Analysis 
Data from ail the selected studies were combined to estimate the 
pooled relative risk (RR) with 95% Cls using a random-effects 
mode!. The presence of heterogeneity across trials was evaluated 
with the Q and 12 statistics, with an I2 value >50% indicating at least 
moderate statistical heterogeneity. 18 Indicative RRs were provided 
when appropriate. Pooling was performed for mortality and for the 
secondary outcomes of readmission, reinfarction, and smoking 
cessation. Recognizing the clinicat heterogeneity between clinical 
controlled trials and before-after studies, we also analyzed data 
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3843 Citations from MEDLfNE. EMBASE. 
CINAHL. PsychrNFO and the Cochrane 
Controlled Cluucal Tnal reg11ter were screened 
by hile and ab1tract 
3742 Citahom exduded on title and 
~ ab1tract . 
1 
57 A1iides iclentitled from 1 . 
reference hsts 
1 
' 
153 Ar11cle1 1elected for füll text rev1ew 
131 1tud1es exclucled on full-text re11ew: 
25 had no 111patient 111terwnhon 
23 had only one CVRF targeted 
13 had no data on 1tuched outcome 
13 had no follow-up outcome 
11 had no pallent-lewl 1nten·t'ntio11 
4 had no control grnup 
5 were 1101 on 1tnched 1op1c 
~ l cL1ta could not be ab1tracted a1 
. 
presented 
15 were mulhple articles repo1ting the 
same studies alreadv selected ll'lthoul 
ackhtional data to abstract 
13 were observahonal only or quahtat11·e 
1tud1es 
3 were rev1ew m11cles 
2 7 A1t1de1 ;ib1tracted 111 det;ul 
Figure 1. Flow diagram of the study selection process. 
separately. In the forest plots, we present data from controlled 
clinical trials on top, before-after studies on the bottom, and 
summary statistics for each study type, as well as an overall 
summary statistic that combines both study types. We do not report 
the overall RR of the prescription rates of proven efficacious 
therapies because of the statistical heterogeneity of >95% for the 12 
statistic observed after pooling. We performed meta-regression to 
analyze clinical and study quality factors on treatment effects, but 
recognizing the generally limited statistical power of meta-
regression, we conducted (and present) a stratified analysis to 
explore the potential influence of study design and varions interven-
tion factors on RR for mortality. The possibility of publication bias 
was assessed through use of Begg's test and with visual assessment 
of a funnel plot. 19 All statistical analyses were performed with Stata 
version 9.1 (Stata Corp, College Station, Tex). 
The authors had full access to and take responsibility for the 
integi:ity of the data. Ali authors have read and agree to the 
manuscript as written. 
Results 
We identified a total of 3843 unique citations through our 
search strategy. After a 2-step screening process, 27 articles 
reporting 26 studies were identified and fulfilled our inclu-
sion criteria.9·10.2o-44 Figure 1 shows details of study selec-
tion. Two articles reporting on the same study but providing 
different outcomes were abstracted for this analysis. 42•43 
There were 7 disagreements among the reviewers about 
eligibility of the studies, leading to a 1< value of 0.76. Ail 
disagreements were resolved by consensus. 
A total of 2467 patients were examined in 16 clinicat 
controlled trials and 38 581 patients in 10 before-after studies. 
Fourteen clinical controlled trials were described as randomized. 
The study characteristics, study population, study quality and 
design, type of intervention, and main findings are presented in 
Table I of the online Data Supplement. Seven studies included 
not only a patient-level intervention but also a healthcare 
provider-level and/or a system-level intervention.9•10•39- 44 Four-
teen studies also included an outpatient component lasting 3 to 
24 months. 9.20,22,26-31,33-36,42 
Meta-Analysis of Ali-Cause Mortality 
Of the 26 studies, 19 provided data on all-cause mortality, 
with an outcome assessment time varying from 1 to 24 
months. Among these, 14 provided follow-up data on mor-
tality at 1 year (see supplementary Table II and Figure 2). 
Among clinical trials, only 1 study reported a statistically 
significant difference in ail-cause mortality between interven-
tion and control patients at 1 year, 23 whereas 4 before-after 
studies did so.9 •10•39•44 The overall pooled RR for ail-cause 
mortality was 0.78 (95% CI, 0.71 to 0.86; P for heterogene-
ity=0.28; I2= 14%) using a random-effect mode!. The pooled 
RR for 1-year ail-cause mortality was 0.79 (95% CI, 0.69 to 
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panel A • Ali cause mortality 
Sludy (year of publication) 
Conlrolled clrnical trials (CCT) 
Oldenburg ( 1985) 
Hedbàck ( 1987) 
Maoland i 19871 --Ill 
Thompson ( 1990) 
Frldlund ( 1991) 
van E~deren·van Kemenade ( 189·0 •-~---
DeBusk (1994) 
Linden (1995) 
Johnslon (2000) 
Nordmann (2001) 
Mayou (2002) 
overall for CCT (95% Cl) 
Before·afler studios (BAS) 
Kushnir ( 1976) 
Srnlzi ( 1980) -·· 
Young (1982) 
Holmboo ( 1999) 
fonarow (2001) 
Lappo (2004) 
Eagle (2005) 
ovcroll for BAS (95% Cl) 
overall (95% Cl) 
1 
.1 
-- 11111 
"' 
11111-
1111 
Panel B • Ali cause mottallty atone year 
Study (year of publication) 
Conlrolled clinical lrials (CCT) 
Oldenburg ( 1985) 
Hedback ( 1987) 
~. 1----··--
---
Maeland ( 1987) 
--11--:J 
: 1 
Frld1und(1991) -.----11-~-:--
van Elderen·van Kemenade ( 1994) --+L,~ -11-~­
, 1 
DeBusk ( 1994) ·• 
Johnslon (2000) -; 11111 
-111L Nordmann (2001) 
Mayou (2002) 
Overnll for CCT (95% Cl) 
Before-afler studies (BAS) 
Scalzl ( 1980) ,_ --
Young (1982) 
Fonarow (2001) 
Lappe (2004) 
Eagle (2005) 
Overall for BAS (95% Cl) 
Overatt (95% Cl) 
'1 
---11111----
__ ., 
Risk ratio 
.1 10 Risk ratio 
Risk ratio 
(95% Cl) 
5.00 (0 30,84 73) 
1. 16 (0.56,2.38) 
0.21 (0.05.0.97) 
0.50 (0.05,5.22) 
OAO (0.04,3.70) 
3 OO (0.33,27 23) 
1.20 (0.52,2.72) 
0.95(0.06,14 22) 
1 35 (0.27,6.65) 
0.69 (0.25, 1.86) 
0.69 (0.12,3.98) 
0.94 (0.63, 1.40) 
0.00(O.17,4.67) 
0.23(0.01,5.32) 
0.82 (0.23,2.98) 
0.68 (0.48,0.95) 
0.47(0.22,100) 
0.73 (0.68,0.78) 
0.87 (0.78,0.96) 
0,77 (0.67,0.87) 
0.78 (0.71,0.86) 
Risi< ratio 
(95%CI) 
5.00 (0 30.84.73) 
1.16 (0.56,2.38) 
021 (0.05.0.97) 
040 (Q.011,3.70) 
3.00 (0.33,27 23) 
1.20 (0.52,2.72) 
1.35 (0.27,6.65) 
0.69 (0.25, l.86) 
0.69 (0.12,3.98) 
0.96 (0.64.1.44) 
0.23 (O.Ot,5.32) 
0.82 (0.23.2.98) 
0.47 (0.22, l.00) 
O. 73 (0.68,0. 78) 
0.87 (0.78,0.96) 
o. 77 (0.66,0,90) 
o. 79 (0.69,0.92) 
0.92), with a value for statistical heterogeneity of P=0.12 and 
an I2 of 32%. 
The Table presents meta-analysis results for all-cause 
mortality at 1 year stratified by a number of important clinical 
factors and study design factors. First, the study design 
seemed to have an effect on the results. For clinical trials, the 
RR was 0.96 (95% CI, 0.64 to 1.44) based on analysis of 99 
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98 
32 
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32145 
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37339 
39236 
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siie 
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6.1 
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~1~ Welght 
2 1 
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33 
3.4 
24 2 
6.5 
16.6 
54 
100 
0.2 
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4.0 
49.2 
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Figure 2. A, Impact of interventions on ail-cause 
mortality (A; n=18 studies) and ail-cause mortality 
at 1 year (B; n=14 studies). 
deaths versus 0.77 (95% CI, 0.66 to 0.90) for before-after 
studies that examined 3680 deaths. Second, if the intervention 
involved only patients through counseling and education, the 
RR was 0.93 (95% CI, 0.63 to 1.36), whereas it was 0.77 
(95% CI, 0.65 to 0.92) if the intervention also included a 
provider-level or system-level intervention. Third, among the 
studied interventions, the continued outpatient component did 
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Table. Stratified Analysis of Ali-Cause Mortality for 
ln-Hospital Interventions 
Variable Studies, n RR 95% Cl 
Mortality after discharge (from 2 ma ta 18 0.78 0.71-0.86 
1 y), all studies 
Mortality at 1 y only 14 0.79 0.69-0.92 
Design of study 
Controlled clinical trials 9 0.96 0.64-1.44 
Before-after studies 5 0.77 0.66-0.90 
Level of intervention 
Patient-level only 11 0.93 0.63-1.36 
Patient-level + healthcare 3 0.77 0.65-0.92 
provider-/system-level intervention 
Continuing intervention in the outpatient 
setting 
Yes 9 0.84 0.58-1.22 
No 5 0.78 0.65-0.94 
Targets an increase in prescription 
rates of proven efficacious medication 
Yes 6 0.80 0.68-0.93 
No 8 0.75 0.39-1.46 
not seem to change the apparent benefit of interventions 
notably (for interventions with a continuing outpatient com-
ponent: RR, 0.84; 95% CI, 0.58 to 1.22; for interventions 
without a continuing outpatient component: RR, 0.78; 95% 
CI, 0.65 to 0.94). Fourth, interventions targeting an increase 
in use of proven efficacious medications were associated with 
a statistically significant beneficial effect (RR, 0.80; 95% CI, 
0.68 to 0.93) that was not observed among the interventions 
not targeting an increase in these medications (RR, 0.75; 95% 
CI, 0.39 to 1.46), although with similar effect sizes. 
There was no evidence of asymmetry in the. funnel plot 
analysis for mortality at 1 year in both .overall and separate 
analyses by study design (data not shown), and Begg's test 
was correspondingly not significant (P>0.60 for all associa-
tions), findings that make significant publication bias un-
likely. However, because our analyses are based on a limited 
number of studies, publîcation bias is still not definitively 
excluded.19 
Meta-Analysis of Secondary Outcomes 
Figure 3 and supplementary Table II present information on 
readmission rates, reinfarction rates, and smoking cessation 
rates. Eleven of the 26 included studies provided information 
on readmission rates or reinfarction rates.9,21-23,26,32,38.40.41,43,44 
The -definition of readmission and reinfarction varied across 
studies (see supplementary Table II), and time of readmission 
or reinfarction assessment ranged from 1 to 12 months. For 1 
study,40 we considered the combined outcome of death or 
readmission as the readmission rate because separate data 
were not available. The pooled RR for readmission between 
the intervention and control groups was 0.84 (95% CI, 0.73 to 
0.98; P for heterogeneity=0.16; I2 =32%; Figure 3). In 
stratified analyses by study design, we found a pattern for 
readmission rate similar to that for all-cause mortality. For 
clinical trials, the RR was 0.96 (95% CI, 0.79 to 1.17) based 
on analysis of274 readmissions versus 0.71 (95% CI, 0.54 to 
0.94) for before-after studies that examined 6586 readmis-
sions. For reinfarction, the RR was 0.59 (95% CI, 0.32 to 
1.07), but pooled results should be considered with caution 
because of significant statistical heterogeneity (P=0.04, 
I2 =90%). For clinical trials, the RR was 0.51 (95% CI, 0.23 
to 1.13) based on analysis of 87 reinfarctions versus 0.81 
(95% CI, 0.20 to 3.31) for before-after studies that examined 
41 reinfarctions. This stratified analysis also should be 
interpreted with caution because of the small number of 
studied outcomes. 
Thirteen studies reported the smoking cessation rates 
at various time points ranging from 6 weeks to 18 
months.20,22-24,26-29,31-33 .3 8 .42 For 1 study, data could not be 
abstracted for statistical analysis because it did not provide 
the number of smokers at the beginning of the study. 38 
In-hospital interventions showed increased smoking ces-
sation rates (RR, 1.29; 95% CI, 1.02 to 1.63), but there was 
evidence of heterogeneity (P for heterogeneity = 0.001; 
I2=66%; Figure 3). 
Figure 4 and supplementary Table II present information 
on the 7 studies that targeted an increase in use of proven 
efficacious therapies at discharge.9· 10•26·39·40·43·44 Most studies 
showed a significant increase in prescription of each of these 
treatments. However, it should be noted that 1 study, the 
before-after study by Fonarow and colleagues,9 showed 
particularly positive results. Because of its combined large 
size and strongly positive results, this study introduced 
significant statistical heterogeneity of findings across studies, 
a finding that led us to avoid pooling of RRs for use of 
efficacious therapies. 
Discussion 
The evidence summarized in this review suggests benefit 
from in-hospital interventions for multiple outcomes, includ-
ing mortality. However, the evidence is not definitive; a 
number of caveats and questions emerge from our results. 
First, the possible mortality benefit is statistically significant 
only in before-after studies. Second, those before-after stud-
ies are the studies in which the interventions were multilevel 
interventions that also targeted an increase in prescription 
rates of proven efficacious therapies. Third, there was both 
clinical and statistical heterogeneity for some of the end 
points assessed. 
A prior nonsystematic review from 1992 on the benefits 
from in-hospital education after myocardial infarction that 
considered only isolated patient-level interventions found no 
significant reduction in mortality despite improved CVRF 
control.5 We found similar results by looking only at the 
clinical trials included in our meta-analysis. The studies 
reviewed were mainly isolated patient-level interventions, 
with inpatient education and counseling as the major inter-
ventions; collectively, such studies suggest an improved 
smoking cessation rate associated with the interventions. Yet, 
despite such benefits, the overall effect on mortality of 
isolated patient-level interventions appears to be modest. It 
needs to be noted, however, that low statistical power and 
event rates in these clinical trials (ie, a total of 104 deaths 
studied) might be contributing to their equivocal findings. 
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Figure 3. Impact of interventions on readmission rates (A; n=îü studies), reinfarction rates (B; n=5 studies), and smoking cessa-
tion (C; n= 12 studies). 
Individual studies in heart failure patients have shown that 
a major effect on mortality can be expected by increasing the 
prescription rate of proven efficacious therapies.45 In-hospital 
initiation of evidence-based cardiovascular therapies and 
patient education seem to improve long-term patient compli-
ance and clinical outcomes.8•46 This might be the mechanistic 
clue to the observed benefit in mortality outcomes because 
these factors were the target of the interventions assessed in 
most of the identified before-after studies. 
We have asserted that the evidence of mortality benefit 
from such interventions is promising but not definitive 
because the significant mortality benefit is seen only in 
before-after studies. A large-cluster randomized controlled 
trial could test the efficacy of multilevel, in-hospital preven-
tion more definitively. Accordingly, one possible proposal for 
the needed "next research step" would be to call for a 
large-cluster randomized controlled trial comparing a major 
secondary prevention intervention with usual care. However, 
some may already accept the benefit of multilevel interven-
tions based on existing evidence and instead propose that 
future studies should move beyond comparisons with usual 
care to instead assess the specific elements of interventions 
that are most effective. For example, a relevant study ques-
tion would be whether interventions need to be continued 
longitudinally in the outpatient setting versus simply admin-
istered during hospitalization. Our study did not suggest a 
significant difference in efficacy on this factor, but a random-
ized comparison would be more definitive. Similarly, future 
studies could formally assess whether interventions should 
rely only on system-level components without patient-level 
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Figure 4. Impact of interventions on prescription rates of antiplatelet agents (A; n=6 studies), /3-blockers (B; n=6 studies), angiotensin-
converting enzyme inhibitors (C; n=6 studies), and lipid-lowering drugs at discharge (D; n=4 studies). 
intervention versus other combinations of levels of interven-
tion. Our conceptual categorization of secondary prevention 
programs by levels of intervention should facilitate future 
evaluations of such interventions. 
The major limitation of our systematic review (inherent to 
the studies that we have systematically reviewed) is that the 
reported mortality results rely maînly on data from before-
after studies. Because of ongoing trends of both increased use 
of proven efficacious therapies and decreased cardiovascular 
mortality,47.48 the outcome benefits seen in this study could 
relate to weakness of study design rather than the interven-
tions. The Guidelines Applied to Practice (GAP) project tried 
to control this factor through a rapid cycle quality improve-
ment strategy, thereby reducing the time for outcome mea-
surement, and showed a reduction in mortality at 1 year. rn 
Furthermore, the same group compared process outcomes of 
11 contrai hospitals that wanted to participate in GAP but 
were not selected relative to 10 GAP intervention hospitals 
and demonstrated that "wanting to improve" did not achieve 
the degree of change in process outcomes observed in 
participating hospitals.49 Also of note, Lappe and colleagues44 
provided data on mortality trends in a study region of interest 
and found that a secondary prevention intervention program 
was probably contributing to improved outcomes over and 
above the trends in their study region. 
There are other limitations in this body of literature. First, 
for most of the studies identified, mortality was not a primary 
outcome, and as a result, the monitoring of this outcome may 
not have been optimal in all studies. Second, there was major 
clinical heterogeneîty in the interventions studied, and our 
interpretation of interventions also was challenged by hetero-
geneity in the reporting of some .outcomes. Smoking cessa-
tion rates were abstracted, but only 1 study provided a 
confirmation of smoking cessation by cotînine level measure-
ment.28 The definitions of readmission rates also were nu-
merous, with some studies considering same-cause readmis-
sions and others all-cause readmissions. For the studies 
reporting data on reinfarction rate, there was no definition of 
reinfarction in the methods section for most of them. The 
meta-analysis of secondary outcomes such as reinfarction and 
smoking cessation led to RRs with significant statistical 
heterogeneity, and these pooled data should be interpreted 
with caution. Finally, we caution that although we carefully 
reviewed the full text of rehabilitation interventions and 
screened the reference lists of former systematic reviews on 
outpatient rehabilitation, 3 .4 it is possible that our search 
strategy might have rnissed some studies on secondary 
prevention interventions in the outpatient setting that also had 
a component beginning during the hospital stay. 
Conclusions 
The evidence on the efficacy of in-hospital, patient-level 
interventions for secondary prevention after acute coronary 
disease is promising but not definitive. Because a significant 
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reduction in mortality has been shown only in the before-after 
studies performed to date, larger randomized controlled trials 
with sufficient statistical power may be needed to confirm 
these promising findings. However, there may no longer be 
sufficient equipoise to study multilevel inpatient interven-
tions on secondary prevention versus merely usual care. 
Future studies may be more relevant to providers and partic-
ipants if they move toward randomized studies assessing the 
components of interventions that contribute the most to 
improved outcomes. Our findings suggest that interventions 
may be more effective when they target not only the patient 
but also the providers and the healthcare system. 
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CLINICAL PERSPECTIVE 
Secondary prevention programs for patients experiencing an acute coronary syndrome have been shown to be effective in 
the outpatient setting. Interest in the inpatient setting for secondary prevention is heightened by the recognized potential 
of hospitalization after an acute disease as a "teachable moment" for behavioral change that may increase the benefit of 
counseling interventions delivered to hospitalized patients. Barly in-hospital initiation of medications also might increase 
the likelihood of being adequately treated. In recent years, multiple studies have assessed pragmatic interventions targeting 
patient education and/or an increase in prescription rates by physicians. The present work pools the results of the existing 
studies to determine whether in-hospital, patient-level interventions targeting multiple cardiovascular risk factors reduce 
ail-cause mortality after an acute coronary syndrome. We included controlled clinical trials and before-after studies and 
classified the interventions as patient-level interventions (ie, education or counse!ing interventions) with or without 
associated healthcare provider-level interventions (eg, improving physician skills and effectiveness in counseling through 
an educational program) and/or system-level interventions (eg, facility outcome reporting). Overall, the studied 
interventions seemed to reduce the risk of ail-cause mortality at 1 year. However, the apparent benefit depended on study 
design and the level of intervention. Only interventions including a provider- or system-level intervention suggested 
reduced mortality compared with patient-level-only interventions. Because only before-after studies suggest a significant 
reduction in mortality, the evidence for in-hospital, patient-level interventions for secondary prevention is promising but 
not definitive. Future research should formally test which components of interventions provide the greatest benefit. 
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